Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
about
miR-181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expressionTetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapySynergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer CellsHepatocellular carcinoma: Where are we?Current systemic treatment of hepatocellular carcinoma: A review of the literatureActivation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cellsSynergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cellsBufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum StressTransposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.Designing a broad-spectrum integrative approach for cancer prevention and treatment.Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cellsSC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinomaEfficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyRole of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular CarcinomaActivation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical EvidenceHBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3.Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinomaInactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer.Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancerA data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides.Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.Multi-omics in prognosis of hepatocellular carcinoma.Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
P2860
Q26744201-9283DF46-2579-474A-87C1-F559000DDB8AQ26749391-45E326F2-D728-48F1-B4DF-F52237A1CF8EQ26752653-A1A5E5A1-4853-4603-B933-8637A7567E97Q26765182-44ECE404-D284-4B35-BB2D-C4BE32ADDA5BQ27026036-88B9802D-15C4-435C-8906-432BD14E6AEDQ28397198-1D4EDA44-1009-4535-98AA-C40B906A7FCBQ28539940-D7FACE7E-6AB6-4A28-A412-236DDDD61699Q28548246-FFDAD951-6BFD-488B-B27C-28CC04633B4AQ30368024-D38EF6E9-4C24-4E06-84EF-E39D48651A07Q30736359-311114D4-4C79-438C-8544-894B9759EE45Q34292802-B198B7AC-B9A3-4D58-9C9E-7B144050FDBAQ34347235-C1A9FC9F-D0C7-400A-8A55-0D6A1B71FC50Q34458029-913F1EED-FD97-44C6-B916-0D901F0A1CB4Q34728237-D31B83B8-4986-43FB-BD69-AE20D1E8C507Q34995167-34D0712A-C811-4226-8E86-932B0676A622Q35182909-D6FE0676-824A-4CF8-80E7-DE222A61BB7EQ35870450-81229ABD-4C61-49F3-A755-65B2F1A00F7BQ36244298-BE354B91-EA4A-4C54-821A-A8527D2F2DC2Q36675015-FC541B8E-EC98-4C92-BE98-C9FA3255AB42Q36729450-D4A946E0-0EB1-4429-A92C-0FB1221D7F4AQ36866377-08C04E55-B71F-4B44-9218-30D5661C355AQ37108804-5623C34C-B643-4701-AE78-7C37A3B8513EQ37141152-C692FA52-BCAD-44E3-B61F-F4DB69B37723Q37613829-521A33F6-1DE8-4DD1-B40C-368B7F6CA2EFQ37715399-6BE11E7D-3864-4467-B579-9612EFE7C502Q38632417-9F6D8750-A2A3-448C-9B23-74D6876C04BAQ38801405-027C62B9-94BF-44B4-B968-59A83F847154Q38919788-680A4FE7-B06E-4608-9E10-F4A8DA89F6A2Q38923977-1BA1A9EE-4E99-416C-A9FC-14A0CE025876Q38982260-C7166BAF-767B-42DB-AE32-66E86C1A8F6EQ38999290-CB5AF7FA-FC1C-4127-B3D2-9F3384D17D86Q39270408-67DC4A1E-E55F-4B8F-A4DD-CE8BDD859E34Q40100642-C334D91D-46D4-4958-B3C1-BEA3D5274FF2Q41126784-FFC527DD-263E-45B5-821E-3AD3F9CC0ECCQ41448132-F6F0EFD4-8675-4E8D-ACD0-D6A91CC3D6D1Q41667581-9F27C1FE-720F-4A10-9955-ED3D7049247AQ42105382-73D0DBC7-B704-4457-BC51-EDA43D61A2E8Q42703579-9ADFED91-74FE-4259-82F4-E19145132DDAQ43105015-7A915540-043D-496E-87D3-E9754A284B00Q43905855-945D726A-DEC8-4594-B7CC-C0DD32C37FF7
P2860
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanisms of resistance to so ...... es in hepatocellular carcinoma
@en
Mechanisms of resistance to so ...... s in hepatocellular carcinoma.
@nl
type
label
Mechanisms of resistance to so ...... es in hepatocellular carcinoma
@en
Mechanisms of resistance to so ...... s in hepatocellular carcinoma.
@nl
prefLabel
Mechanisms of resistance to so ...... es in hepatocellular carcinoma
@en
Mechanisms of resistance to so ...... s in hepatocellular carcinoma.
@nl
P2860
P356
P1476
Mechanisms of resistance to so ...... es in hepatocellular carcinoma
@en
P2093
P2860
P304
P356
10.4254/WJH.V5.I7.345
P577
2013-07-01T00:00:00Z